Integra Lifesciences Holdings (IART) Share-based Compensation (2009 - 2026)

Integra Lifesciences Holdings has reported Share-based Compensation for 18 years, with the latest figure at $5.8 million in Q2 2026.

• Quarterly Share-based Compensation rose 16.21% year-over-year to $5.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $22.4 million (up 19.94% YoY) and the FY2025 annual result came in at $18.6 million, down 23.77% from the prior year.
• Share-based Compensation climbed to $5.8 million in Q2 2026 per IART's latest filing, from $5.2 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $14.0 million in Q2 2022 and troughed at $1.1 million in Q3 2022.
• A 5-year average of $5.7 million and a median of $5.5 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation slumped 85.26% in 2022, then soared 378.02% in 2023.
• Over 5 years, Share-based Compensation stood at $3.4 million in 2022, then surged by 71.44% to $5.8 million in 2023, then grew by 23.46% to $7.2 million in 2024, then slipped by 18.37% to $5.8 million in 2025, then rose by 0.1% to $5.8 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $5.8 million, $5.2 million, and $5.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.